Rational design of anti-GITR-based combination immunotherapy.
Animals
Antibodies, Monoclonal, Humanized
/ therapeutic use
Biomarkers, Tumor
/ immunology
Drug Design
Glucocorticoid-Induced TNFR-Related Protein
/ agonists
Humans
Immunotherapy
/ methods
Melanoma, Experimental
/ immunology
Mice
Mice, Inbred C57BL
Neoplasms
/ immunology
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
T-Lymphocytes, Regulatory
/ immunology
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
14
02
2019
accepted:
12
03
2019
pubmed:
1
5
2019
medline:
11
7
2019
entrez:
1
5
2019
Statut:
ppublish
Résumé
Modulating T cell homeostatic mechanisms with checkpoint blockade can efficiently promote endogenous anti-tumor T cell responses
Identifiants
pubmed: 31036879
doi: 10.1038/s41591-019-0420-8
pii: 10.1038/s41591-019-0420-8
pmc: PMC7457830
mid: NIHMS1616665
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biomarkers, Tumor
0
Glucocorticoid-Induced TNFR-Related Protein
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
TNFRSF18 protein, human
0
Banques de données
ClinicalTrials.gov
['NCT02628574']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
759-766Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215136
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Lancet Oncol. 2017 Jan;18(1):31-41
pubmed: 27932067
Curr Opin Immunol. 2012 Apr;24(2):217-24
pubmed: 22245556
Oncoimmunology. 2017 Feb 3;6(3):e1280645
pubmed: 28405505
J Immunol. 2007 Nov 1;179(9):5916-26
pubmed: 17947665
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Cancer Res. 2017 Mar 1;77(5):1108-1118
pubmed: 28122327
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
J Exp Med. 2005 Oct 3;202(7):885-91
pubmed: 16186187
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Br J Pharmacol. 2012 Apr;165(7):2089-99
pubmed: 22029729
Cancer Res. 2008 Jul 15;68(14):5948-54
pubmed: 18632650
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Int J Cancer. 2013 Mar 15;132(6):1341-50
pubmed: 22907255
Nature. 2016 Aug 2;537(7620):412-428
pubmed: 27501245
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Cancer Immunol Res. 2013 Nov;1(5):320-31
pubmed: 24416730
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Cancer Cell. 2018 Apr 9;33(4):581-598
pubmed: 29634946
Nat Immunol. 2002 Feb;3(2):135-42
pubmed: 11812990
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
J Clin Invest. 2006 Jul;116(7):1935-45
pubmed: 16778987
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Nat Med. 2016 Jun;22(6):679-84
pubmed: 27111280
Sci Rep. 2015 Mar 31;5:9534
pubmed: 25826597
J Exp Med. 2010 Jan 18;207(1):223-35
pubmed: 20065066
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Cancer Res. 2017 Aug 15;77(16):4378-4388
pubmed: 28611044
J Immunol. 2004 Jun 15;172(12):7306-14
pubmed: 15187106
PLoS One. 2010 May 03;5(5):e10436
pubmed: 20454651
Blood. 2005 Apr 1;105(7):2845-51
pubmed: 15591118
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Cancer Cell. 2018 Jun 11;33(6):1017-1032.e7
pubmed: 29894689
J Exp Med. 2004 Sep 20;200(6):771-82
pubmed: 15381730
Immunity. 2009 Jun 19;30(6):899-911
pubmed: 19464196
Clin Cancer Res. 2010 May 15;16(10):2781-91
pubmed: 20460483